SALVATORE, LISA
 Distribuzione geografica
Continente #
NA - Nord America 1.203
EU - Europa 430
AS - Asia 199
AF - Africa 38
OC - Oceania 1
Totale 1.871
Nazione #
US - Stati Uniti d'America 1.178
IT - Italia 124
DE - Germania 85
SG - Singapore 78
CN - Cina 75
SE - Svezia 70
BG - Bulgaria 46
GB - Regno Unito 30
CA - Canada 25
FR - Francia 23
VN - Vietnam 21
AT - Austria 18
SN - Senegal 16
CI - Costa d'Avorio 13
FI - Finlandia 11
TR - Turchia 10
NG - Nigeria 8
RU - Federazione Russa 8
IN - India 6
UA - Ucraina 5
HK - Hong Kong 4
CH - Svizzera 2
JP - Giappone 2
NL - Olanda 2
NO - Norvegia 2
AU - Australia 1
BA - Bosnia-Erzegovina 1
BJ - Benin 1
CZ - Repubblica Ceca 1
EE - Estonia 1
IL - Israele 1
KR - Corea 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
Totale 1.871
Città #
Woodbridge 231
Fairfield 149
Ashburn 94
Chandler 80
Seattle 71
Houston 69
Cambridge 59
Ann Arbor 51
Wilmington 48
Sofia 46
Singapore 39
New York 36
Beijing 30
Santa Clara 28
Pisa 27
Princeton 23
Boardman 21
Lawrence 18
Ottawa 18
Vienna 18
Des Moines 17
Dakar 16
Medford 16
Bremen 14
Abidjan 13
Dong Ket 13
Florence 13
Dearborn 12
London 12
Marseille 12
Istanbul 10
Redwood City 9
Lagos 8
Düsseldorf 7
Nanjing 7
Lancaster 6
Phoenix 6
Seacroft 6
Serra 6
Changsha 5
Kunming 5
Positano 5
Rome 5
San Diego 5
Turin 5
Boulder 4
Frankfurt am Main 4
Hong Kong 4
Lusciano 4
Polverigi 4
San Francisco 4
Shenyang 4
Toronto 4
Hebei 3
Leawood 3
Nürnberg 3
Ogden 3
Genoa 2
Guangzhou 2
Hangzhou 2
Lecce 2
Los Angeles 2
Nanchang 2
Oslo 2
Quanzhou 2
San Giuliano Terme 2
Shanghai 2
Tianjin 2
Aprilia 1
Berlin 1
Bern 1
Bracknell 1
Bratislava 1
Buffalo 1
Capannori 1
Capurso 1
Chengdu 1
Chiswick 1
Cotonou 1
Council Bluffs 1
Cutrofiano 1
Dallas 1
Duncan 1
Esslingen am Neckar 1
Fuzhou 1
Gallarate 1
Geneve 1
Genova 1
Grafing 1
Haifa 1
Hamilton 1
Hefei 1
Helsinki 1
Indiana 1
Indore 1
Jinan 1
Jüchen 1
Kent 1
Kyiv 1
Leipzig 1
Totale 1.487
Nome #
An interview with Alfredo Falcone and Lisa Salvatore: RECOURSE and trifluridine/tipiracil in metastatic colorectal cancer 147
TRIBE-2: A phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group 145
TAS-102 for the treatment of metastatic colorectal cancer 135
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer 121
Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients 117
Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer 116
TRIPLETE: A randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer 111
Location of primary tumor and benefit from anti-epidermal growth factorreceptor monoclonalantibodies in patients with RAS and BRAF wild-typemetastatic colorectal cancer 105
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer 100
null 98
KRAS status and risk of venous thromboembolic events in patients with metastatic colorectal cancer: a case-control study. 94
Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. 91
null 85
Circulating microRNAs in metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib 79
Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer 77
Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial 77
Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer 64
Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study 47
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer 28
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study 25
First-line chemotherapy for mCRC-a review and evidence-based algorithm 24
Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study 22
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer 21
Totale 1.929
Categoria #
all - tutte 6.276
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.276


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020306 0 0 0 0 61 60 45 38 41 27 23 11
2020/2021162 10 9 5 12 13 5 9 6 40 11 19 23
2021/2022214 3 9 2 3 34 36 4 5 19 13 9 77
2022/2023303 24 48 20 34 31 35 2 14 72 2 18 3
2023/2024179 14 12 26 8 23 28 16 17 4 3 8 20
2024/2025118 5 22 40 28 23 0 0 0 0 0 0 0
Totale 1.929